Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 179 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Lung Resection Clear all
Terminated Phase 1 Interventional

Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

NCT01313429
View directory record Official record
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
Interventions
Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

NCT03535545
View directory record Official record
Conditions
Pulmonary Fibrosis, Lung Cancer
Interventions
[68Ga]CBP8, PET Imaging
Drug · Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Completed No phase listed Observational

Evaluating Intuitive 3D Models in Preoperative Surgical Planning for Thoracic and Colorectal Procedures.

NCT06434727
View directory record Official record
Conditions
Thoracic, Colorectal Disorders
Interventions
observational study
Other
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Timeline
2024 – 2025
U.S. locations
4
States / cities
Baton Rouge, Louisiana • Manhasset, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Withdrawn No phase listed Observational

A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer

NCT01237171
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer
Interventions
Cesium-131 Brachytherapy Seed
Radiation
Lead sponsor
IsoRay Medical, Inc.
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional Results available

Study of ECHELON ENDOPATH(TM) Staple Line Reinforcement

NCT04544865
View directory record Official record
Conditions
Gastric Procedures, Lung Resection Procedures
Interventions
Staple Line Reinforcement
Device
Lead sponsor
Ethicon Endo-Surgery
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Indianapolis, Indiana • Baton Rouge, Louisiana • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Phase 4 Interventional

Cryospray Ablation of Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung

NCT00747773
View directory record Official record
Conditions
Lung Cancer
Interventions
CryoSpray Ablation System
Device
Lead sponsor
CSA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Jul 23, 2026, 6:11 PM EDT
Not listed No phase listed Observational

Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection

NCT00450125
View directory record Official record
Conditions
Lung Cancer
Interventions
Six-Minute Walk Test, Exercise stress test
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 90 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting No phase listed Observational

Biomarkers of Resiliency In Childhood Cancer Surgery

NCT06674811
View directory record Official record
Conditions
Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors, Childhood Soft Tissue Sarcoma, Childhood Bone Sarcoma, Childhood Malignant Intestinal Neoplasm, Childhood Malignant Liver Neoplasm, Childhood Malignant Lung Neoplasm, Childhood Malignant Ovarian Neoplasm, Childhood Malignant Pleural Neoplasm, Childhood Neuroblastic Tumor, Childhood Sarcoma
Interventions
Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Phase 1 Interventional

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

NCT00254384
View directory record Official record
Conditions
Recurrent Lung Non-Small Cell Carcinoma, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Cisplatin, Docetaxel, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Jul 23, 2026, 6:11 PM EDT
Terminated Not applicable Interventional Results available

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

NCT00840749
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
CyberKnife Stereotactic Radiotherapy, Surgery
Radiation · Procedure
Lead sponsor
Accuray Incorporated
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
14
States / cities
Fresno, California • Colorado Springs, Colorado • Lone Tree, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Phase 3 Interventional Results available

Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study

NCT03306992
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Secondary Lung Cancer
Interventions
Personalized Exercise Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

NCT03158129
View directory record Official record
Conditions
Stage I Lung Non-Small Cell Cancer AJCC v7, Stage IA Lung Non-Small Cell Carcinoma AJCC v7, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Carboplatin, Cisplatin, Docetaxel, Ipilimumab, Nivolumab, Pemetrexed
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens

NCT06252129
View directory record Official record
Conditions
Lung Cancer, Lymph Node Metastasis, Pathologic Processes
Interventions
Subjects undergoing a lung specimen lymph node dissection, Control group
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Terminated Not applicable Interventional Results available

Bronchoscopic Laser Ablation of Peripheral Lung Tumors

NCT03707925
View directory record Official record
Conditions
Lung Carcinoid Tumor, Lung Non-Small Cell Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Cone-Beam Computed Tomography, Conventional Surgery, Laser Ablation
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting No phase listed Observational

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

NCT06626243
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Scientific Institute San Raffaele
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Miami, Florida • New York, New York • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Jul 23, 2026, 6:11 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199
View directory record Official record
Conditions
NSCLC, Stage IB-IIIA, Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations
Interventions
Cisplatin, Carboplatin, Pemetrexed, TAS6417, Zipalertinib Matching-placebo
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
30
States / cities
Anchorage, Alaska • Duarte, California • Irvine, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting Phase 1 Interventional

Indocyanine Green (ICG) Guided Tumor Resection

NCT04084067
View directory record Official record
Conditions
Neoplastic Disease, Solid Tumor
Interventions
Indocyanine Green
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Terminated Phase 2 Interventional

Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

NCT00087269
View directory record Official record
Conditions
Stage IA Non-small Cell Lung Cancer, Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, therapeutic endoscopic surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study

NCT00756886
View directory record Official record
Conditions
Arrhythmia
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer

NCT07276789
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
LS301-IT 0.1 mg/kg
Drug
Lead sponsor
Integro Theranostics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 6:11 PM EDT
Withdrawn Not applicable Interventional

Pneumostasis With Use of Bio-absorbable Mesh and Fibrin Sealant in Lung Resection

NCT04317924
View directory record Official record
Conditions
Air Leak From Lung
Interventions
Polyglycolic acid felt, Standard of care
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Jul 23, 2026, 6:11 PM EDT
Completed Phase 2 Interventional Results available

A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor

NCT01853878
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Newark, Delaware • Springfield, Illinois • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 23, 2026, 6:11 PM EDT
Completed No phase listed Observational

Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer

NCT02848872
View directory record Official record
Conditions
Non-small Cell Lung Carcinoma
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 23, 2026, 6:11 PM EDT
Recruiting Phase 2 Interventional

Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

NCT04067830
View directory record Official record
Conditions
Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions
Best Practice, Laparoscopic Surgery, Quality-of-Life Assessment, Questionnaire Administration, Respiratory Muscle Training Device, Video-Assisted Thoracic Surgery
Other · Procedure · Device
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 6:11 PM EDT